cure for cancer...you can invest, page-268

New update out. Appears some good progress has been made.

Human EBC-46 Phase I/II is nearly finished with 21 patients treated with only 1 more to be treated. It's reported to show a good safety profile with signs of efficacy in all tumours and tumour types treated including melanoma, squamous cell carcinoma, basal cell carcinoma, breast adenocarcinoma, angiosarcoma and lymphangiosarcoma. Even though this is a safety study, FULL TUMOUR DESTRUCTION was reported at the higher dosage cohorts.

Veterinary EBC-46 Pivotal Field Efficacy study (last study) has progressed well. 56 dogs of a total of 120 dogs required have been treated on the Mast Cell Tumour study and 5 of 45 required for the Soft Tissue Sarcoma study. This should be bringing in income in the not too distant future, which will strengthen the company's position.

Wound Healing 1 (WH1) has progressed well in the pre-clinical space.

The company is currently in a trading halt pending the merger of Qbiotics with its parent company Ecobiotics.